Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

MDM2 degrader KT-253

A small molecule protein and selective degrader of the oncoprotein murine double minute 2 (MDM2), with potential immunomodulating and antineoplastic activities. Upon administration, MDM2 degrader KT-253 binds to MDM2 and the E3 (ubiquitin) ligase and targets MDM2 for ubiquitination. This induces proteasome-mediated degradation of MDM2 and prevents its binding to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this MDM2-p53 interaction, the transcriptional activity of p53 is restored and leads to the stabilization of p53 levels. This leads to p53-mediated induction of tumor cell apoptosis. MDM2, a zinc finger protein and a negative regulator of the p53 pathway, is overexpressed in cancer cells; it plays a key role in cancer cell proliferation and survival.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:KT 253
KT-253
KT253
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search